STAT inhibitors for cancer therapy
Muhammad Furqan(Westchester Medical Center), Akintunde Akinleye(Westchester Medical Center), Nikhil Mukhi(SUNY Downstate Health Sciences University), Varun Mittal(New York Medical College), Yamei Chen(New York Medical College), Delong Liu(Westchester Medical Center)
Cited by 184Open Access
Abstract
Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds.
Related Papers
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity
Khandaker Siddiquee, Shumin Zhang, Wayne C. Guida et al.|Proceedings of the National Academy of Sciences|2007|742